Previous clinical studies showed there is a potential value of EGFR-TKI in local advanced EGFR-mutant NSCLC, while the risk of radiation pneumonia in combination of EGFR-TKI with thoracic radiotherapy is unknown. This study aims to explore the safety and efficacy of concurrent almonertinib, a new third-generation EGFR-TKI drug, with radiotherapy in local advanced EGFR-mutant NSCLC patients.
Description: incidence of radiation pneumonitis (≥ grade 3) within 6 month after RadiotherapyMeasure: RP(≥3) Time: 6 months
Description: local control rateMeasure: LCR Time: 1 years
Description: progression-free survival (PFS) defines as intervals from treatment to disease progression or deathMeasure: PFS Time: 2 years
Description: overall survival (OS) intervals from treatment to death or last follow-uoMeasure: OS Time: 2 years
Single Group Assignment
There is one SNP
Inclusion Criteria: - Confirmed histologically or pathologically as non-small cell lung cancer; - According to the eighth edition of the 2015 IASLC international lung cancer staging, imaging staging assessed as inoperable stage III patients (according to the eighth edition of the 2015 IASLC international lung cancer staging); - Blood or tissue EGFR detection is Exon 19 deletion or L858R mutation; - Have not received systemic anti-tumor therapy; - FEV1>0.75L; - Age ≥ 18 years old; - ECOG PS score ≤ 2; - Estimated survival period ≥ 6 months; - Women must undergo surgical sterilization, post-menopausal, or take contraceptive measures during the treatment period and within 3 months after the end; - Sign the informed consent form. --- L858R ---